Cover Image
市場調查報告書

腎上腺腦白質營養不良:全球臨床實驗趨勢

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015

出版商 GlobalData 商品編碼 340879
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺腦白質營養不良:全球臨床實驗趨勢 Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015
出版日期: 2015年08月31日 內容資訊: 英文 70 Pages
簡介

腎上腺腦白質營養不良是以中樞神經系統 (腦和脊髓) 的去髓鞘化和腎上腺功能不全為特徵的遺傳性疾病。

本報告提供腎上腺腦白質營養不良臨床實驗相關之最新趨勢分析,提供您各地區主要國家的臨床實驗數量,臨床實驗的各階段進展,實驗對象採用狀況,並彙整有潛力的贊助商,各企業和研究機關的研究進展,有潛力的藥劑比較等資訊。

簡介

  • 腎上腺腦白質營養不良
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要國家的臨床實驗數量
    • 歐洲主要國家的臨床實驗數量
    • 北美主要國家的臨床實驗數量

G7各國臨床實驗數量:遺傳性疾病治療藥臨床實驗上腎上腺腦白質營養不良的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:遺傳性疾病治療藥臨床實驗上腎上腺腦白質營養不良的比例

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

腎上腺腦白質營養不良治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Bluebird bio, Inc.
    • Aldagen, Inc. (Inactive)
    • NUVISAN GmbH
    • Nutra Pharma Corporation
    • Nuo Therapeutics, Inc.
    • Neuralgene
    • Marcus Foundation Inc
    • Fate Therapeutics, Inc.
    • Celgene Corporation
    • Asklepion Pharmaceuticals, LLC
  • 有代表性的研究機關·醫院臨床實驗概要
    • Duke University
    • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
    • Academic Medical Center
    • Far Eastern Memorial Hospital
    • FDA Office of Orphan Products Development
    • Herbert Irving Comprehensive Cancer Center
    • Institute of Biomedical Investigations of Bellvitge
    • Masonic Cancer Center

5個有代表性的臨床實驗簡介

附錄

目錄
Product Code: GDHC2846CTIDB

GlobalData's clinical trial report, "Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
  • Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Bluebird bio, Inc.
      • Clinical Trial Overview of Bluebird bio, Inc.
      • Aldagen, Inc. (Inactive)
      • Clinical Trial Overview of Aldagen, Inc. (Inactive)
      • NUVISAN GmbH
      • Clinical Trial Overview of NUVISAN GmbH
      • Nutra Pharma Corporation
      • Clinical Trial Overview of Nutra Pharma Corporation
      • Nuo Therapeutics, Inc.
      • Clinical Trial Overview of Nuo Therapeutics, Inc.
      • Neuralgene
      • Clinical Trial Overview of Neuralgene
      • Marcus Foundation Inc
      • Clinical Trial Overview of Marcus Foundation Inc
      • Fate Therapeutics, Inc.
      • Clinical Trial Overview of Fate Therapeutics, Inc.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Asklepion Pharmaceuticals, LLC
      • Clinical Trial Overview of Asklepion Pharmaceuticals, LLC
    • Clinical Trial Overview of Top Institutes / Government
      • Duke University
      • Clinical Trial Overview of Duke University
      • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      • Clinical Trial Overview of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
      • Far Eastern Memorial Hospital
      • Clinical Trial Overview of Far Eastern Memorial Hospital
      • FDA Office of Orphan Products Development
      • Clinical Trial Overview of FDA Office of Orphan Products Development
      • Herbert Irving Comprehensive Cancer Center
      • Clinical Trial Overview of Herbert Irving Comprehensive Cancer Center
      • Institute of Biomedical Investigations of Bellvitge
      • Clinical Trial Overview of Institute of Biomedical Investigations of Bellvitge
      • Masonic Cancer Center
      • Clinical Trial Overview of Masonic Cancer Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluebird bio, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Aldagen, Inc. (Inactive), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by NUVISAN GmbH, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nutra Pharma Corporation, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralgene, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Marcus Foundation Inc, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asklepion Pharmaceuticals, LLC, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Far Eastern Memorial Hospital, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Herbert Irving Comprehensive Cancer Center, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institute of Biomedical Investigations of Bellvitge, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015*

List of Figures

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top